The ticker can refer to a few different companies, but the most frequently discussed stock in recent headlines and analyst coverage is:

​Altimmune, Inc. (NASDAQ: ALT), a clinical-stage biopharmaceutical company.

​📰 Rumours and Key Information for Altimmune, Inc. ($ALT)

​I did not find a specific, recent, widely-reported "trade rumour" (like a merger, acquisition, or partnership rumour) that is generating significant buzz right now for Altimmune, Inc.

​However, here is an overview of the most relevant news and analyst activity, which often drives market speculation:

​Analyst Price Targets: Several Wall Street analysts have recently reiterated or adjusted their price targets for $ALT, with a high degree of forecasted upside from its current price.

​Consensus Rating: The consensus rating among analysts is often Hold or Moderate Buy/Strong Buy depending on the reporting source.

​Average 12-Month Price Target: The average target from analysts typically ranges between $17.40 and $19.75, with the highest individual targets reaching $24.00 to $25.00 (as of early November 2025). This suggests analysts see significant potential long-term growth.@rumour.app #Traderumour $ALT